Chromocell Therapeutics Corporation (CHRO)

1.7700 -0.0200 (-1.12%) At close: 03:16PM EDT

Chromocell Therapeutics Corporation

4400 Route 9 South
Suite 1000
Freehold, NJ 07728
United States
877 265 8266
https://www.chromocell.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 4

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Francis Knuettel II, M.B.A.	CEO, CFO, Treasurer & Secretary	107.5k	N/A	1966
Dr. Eric Lang M.D.	Chief Medical Officer	264.99k	N/A	1963

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Corporate Governance

Chromocell Therapeutics Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.